Administration of tobramycin in the beginning of the hemodialysis session: A novel intradialytic dosing regimen

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 4, 2007, Pages 694-699

  Kamel Mohamed, Osama Hussein ^a   Wahba, Ihab M ^b   Watnick, Suzanne ^b,c   Earle, Sandra B ^d   Bennett, William M ^e,f   Ayres, James W ^f   Munar, Myrna Y ^f  

^a CAIRO UNIVERSITY   (Egypt)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d Findlay University School of Pharmacy   (United States)

^e LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^f OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; TOBRAMYCIN;

AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; CROSSOVER PROCEDURE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TIME;

AGED; ANTI-BACTERIAL AGENTS; CROSS-OVER STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TOBRAMYCIN;

EID: 34548827732     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01600407     Document Type: Article

References (21)

1. Brummett RE, Morrison RB: The incidence of aminoglycoside antibiotic-induced hearing loss. Arch Otolaryngol Head Neck Surg 116: 406-410, 1990
2. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R: The pharmacodynamics of aminoglycosides. Clin Infect Dis 27: 23-27, 1998
3. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL: Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43: 1549-1555, 1999
4. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan K, Bennett WM: Drug Prescribing in Renal Failure: Dosing Guidelines in Adults, 4th Ed., Philadelphia, American College of Physicians, 1999
5. Gailiunas P Jr, Dominguez-Moreno M, Lazarus M, Lowrie EG, Gottlieb MN, Merrill JP: Vestibular toxicity of gentamicin. Incidence in patients receiving long-term hemodialysis therapy. Arch Intern Med 138: 1621-1624, 1978
6. Kisor DF, Watling SM, Zarowitz BJ, Jelliffe RW: Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm. Clin Pharmacokinet 23: 62-68, 1992
7. Matzke GR, Halstenson CE, Keane WF: Hemodialysis elimination rates and clearance of gentamicin and tobramycin. Antimicrob Agents Chemother 25: 128-130, 1984
8. Sheiner LB, Beal SL: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503-512, 1981
9. Chong TK, Piraino B, Bernardini J: Vestibular toxicity due to gentamicin in peritoneal dialysis patients. Perit Dial Int 11: 152-155, 1991
10. Paterson DL, Robson JM, Wagener MM: Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 13: 735-739, 1998
11. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang SM, Zhu X, Lazarus JM: Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 33: 523-534, 1999
12. Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12: 2158-2162, 2001
13. Shemin D, Bostom AG, Laliberty P, Dworkin LD: Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38: 85-90, 2001
14. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT; NECOSAD Study Group: Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 15: 1061-1070, 2004
15. Teigen MM, Duffull S, Dang L, Johnson DW: Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol 46: 1259-1267, 2006
16. Dang L, Duffull S: Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis. J Clin Pharmacol 46: 662-673, 2006
17. Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155: 93-99, 1987
18. Vogelman B, Gudmundsson S, Tumidge J, Leggett J, Craig WA: In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 157: 287-298, 1988
19. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr: Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 43: 623-629, 1999
20. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE: Treatment and outcome of Pseudomonas aeruginosa bacteraemia: An antibiotic pharmacodynamic analysis. J Antimicrob Chemother 52: 668-674, 2003
21. Matsuo H, Hayashi J, Ono K, Andoh K, Andoh Y, Sano Y, Saruki K, Tanaka J, Yamashita M, Nakamura K, Kubo K: Administration of aminoglycosides to hemodialysis patients immediately before dialysis: A new dosing modality. Antimicrob Agents Chemother 41: 2597-2601, 1997